The clofibrate saga: a retrospective commentary
The clofibrate saga: a retrospective commentary
复制标题
DOI：
10.1111/j.1365-2125.2012.04282.x
复制
发表时间：
2012-12-01
影响因子：
3.4
通讯作者：
Oliver, Michael
中科院分区：
文献类型：
--
作者：
Oliver, Michael
背景氯贝特的历史可以追溯到20世纪50年代初。高夫曼是加州大学伯克利校区的物理学家，他发表的一篇论文表明，冠心病患者的血浆胆固醇浓度很高[1]。这些研究基于超速离心分析，显示了一种独特的脂蛋白模式。来自纽约的巴尔用冷降水方法证实了这一点[2]。爱丁堡的George Boyd开发了一种使用纸电泳法的简单微量分析方法[3]，1953年，我们在欧洲发表了第一篇论文，报告称与年龄匹配的对照组相比，冠心病患者的胆固醇浓度更高，尤其是年轻患者[4]。
BackgroundThe start of the story of clofibrate goes back to the early 1950s. Gofman, a physicist in the Berkeley Campus of the University of California, published a paper suggesting that patients with coronary heart disease (CHD) have high plasma concentrations of cholesterol [1]. These studies were based on ultracentrifugal analysis showing a distinctive lipoprotein pattern. Barr from New York confirmed this using a cold precipitation method [2]. George Boyd in Edinburgh developed a simple micromethod of analysis using paper electrophoresis [3] and in 1953 we published the first paper in Europe reporting that patients with CHD have higher concentrations of cholesterol, particularly the younger ones, when compared with an age-matched control group [4].